8-KItem 5.02 · Officer/Director Change
INCYTE CORP (INCY)

Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025.

Filed with the SEC on · Summarized by InvestorsBot

Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025. Former Chairman & CEO; board member since 2014. 8‑K shows no replacement named. $INCY 👋 #CorporateGovernance #Biotech

8‑K filed Dec 12, 2025: Incyte confirms Hoppenot's immediate retirement; filing signed by Richard Hoffman, EVP & General Counsel. Board seat vacant per filing. $INCY 📄 #SEC #Pharma

Hoppenot’s departure removes a long‑tenured director with prior CEO/Chair experience at Incyte. Investors should watch for board composition updates. $INCY 🔍 #CorporateGovernance #Biotech

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from INCYTE CORP

Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…

8-K · March 26, 2026

Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.

8-K · March 26, 2026

FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…

8-K · March 6, 2026

Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…

8-K · February 10, 2026

Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY…

8-K · February 10, 2026